Medical Economics Logo
  • Physicians Money Digest

  • Physicians Financial News

  • Physicians Practice

  • Chief Healthcare Executive

  • Patient Care Online

All NewsCareersLegalMoneyOpinionPhysicians Financial NewsPractice ManagementTechnology
Around the PracticeBetween The LinesClinical ConsultExpert InterviewsMedical Economics PulseMedical World NewsOff The Charts PodcastsPhysician ReportPrimaryViewSlideshows
Academy
Conference CoverageConference Listing
Medical EconomicsPatient Care SupplementSponsored ContentSponsored ResourcesSupplements And Featured Publications
CME/CEJob BoardSubscribe
Financial Advisor Guide
CareersCareersCareersCareersCareersCareersCareersCareersCareers
LegalLegalLegalLegalLegal
Medical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & Technology
Opinion
Physician's Money DigestPhysician's Money DigestPhysician's Money DigestPhysician's Money Digest
PolicyPolicyPolicyPolicyPolicyPolicy
Practice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice Finance
Practice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice Management
Practice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice Technology
Screening
Special ReportsSpecial ReportsSpecial Reports
Spotlight -
  • The benefits of a physician MBA program
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Physician Bootcamp
  • Physician Report
CareersCareersCareersCareersCareersCareersCareersCareersCareers
LegalLegalLegalLegalLegal
Medical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & TechnologyMedical Device & Technology
Opinion
Physician's Money DigestPhysician's Money DigestPhysician's Money DigestPhysician's Money Digest
PolicyPolicyPolicyPolicyPolicyPolicy
Practice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice FinancePractice Finance
Practice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice ManagementPractice Management
Practice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice TechnologyPractice Technology
Screening
Special ReportsSpecial ReportsSpecial Reports
    • Academy
    • CME/CE
    • Job Board
    • Subscribe
Advertisement

News

Article

January 20, 2025

Are popular weight loss drugs putting your patients at risk?

Author(s):

Todd Shryock

Key Takeaways

  • GLP-1 receptor agonists show significant benefits for neurological and behavioral health, reducing risks of addiction and neurocognitive disorders.
  • These drugs modestly reduce cardiovascular risks, with benefits ranging from a 10% to 20% reduction in heart attack and stroke risks.
  • Potential risks include gastrointestinal issues, pancreatitis, and kidney problems, necessitating vigilant monitoring by healthcare providers.
  • Comprehensive evaluation of GLP-1RA drugs' effects across all body systems is crucial to balance their benefits and risks in clinical practice.
SHOW MORE

Surge in GLP-1RA use has researchers looking at all benefits of the drugs, but also the risk to the pancreas and kidneys

Are weight-loss drugs dangerous to patients? ©Tobias Arhelger - stock.adobe.com

Are weight-loss drugs dangerous to patients? ©Tobias Arhelger - stock.adobe.com

The popularity of weight-loss medications such as Ozempic and Wegovy continues to soar, with a new study reporting that one in eight Americans has used these drugs to address diabetes, heart disease, or obesity. Known as glucagon-like peptide-1 receptor agonists (GLP-1RA), these drugs also include Mounjaro and Zepbound, earning the informal label of “miracle drugs” due to their profound effects on weight loss and related health outcomes. However, research from Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care System examined both the extensive benefits and potential risks of the drugs.

In a study published January 20 in Nature Medicine, scientists evaluated the health outcomes of over two million people with diabetes who were prescribed GLP-1RA medications. The findings highlight the drugs' broad effects on neurological and behavioral health, alongside increased risks for specific conditions such as pancreatitis and kidney issues.

“Given the drugs’ newness and skyrocketing popularity, it is important to systematically examine their effects on all body systems — leaving no stone unturned — to understand what they do and what they don’t do,” said senior author Ziyad Al-Aly, M.D., a clinical epidemiologist and nephrologist at Washington University. “Our approach has allowed us to build a comprehensive atlas mapping the associations of GLP-1RA spanning all organ systems.”

Using de-identified medical records from the U.S. Department of Veterans Affairs, the researchers compared 175 health outcomes in veterans taking GLP-1RA drugs versus those prescribed traditional diabetes medications such as Jardiance, Glipizide, and Januvia. The analysis included patients of diverse ages, races, and sexes, providing robust data to inform clinical care.

Among the study's key findings, GLP-1RA drugs were associated with significant benefits to neurological and behavioral health. Patients experienced reduced risks of conditions such as seizures, addiction disorders (including alcohol, cannabis, stimulants, and opioids), suicidal ideation, and psychotic disorders like schizophrenia. The drugs were also linked to lower risks of neurocognitive conditions such as Alzheimer’s disease and dementia.

“Interestingly, GLP-1RA drugs act on receptors expressed in brain areas involved in impulse control, reward, and addiction — potentially explaining their effectiveness in curbing appetite and addiction disorders,” said Al-Aly. “These drugs also reduce inflammation in the brain and result in weight loss; both these factors may improve brain health.”

Echoing previous studies, the research confirmed GLP-1RA drugs’ ability to reduce risks of heart attack, stroke, and other cardiovascular concerns. The magnitude of benefits was modest, generally ranging from a 10% to 20% reduction. Still, Al-Aly emphasized the potential value of these drugs, particularly for conditions with limited treatment options. “The modest effect does not negate the potential value of these drugs, especially for conditions like dementia,” he said. “They are likely most effective when used alongside lifestyle changes or other medications.”

Risks: Pancreatitis, kidney problems, and GI issues

While GLP-1RA drugs show promise, the study also underscored risks, including gastrointestinal issues such as nausea, vomiting, and diarrhea. More notably, researchers identified associations with rare but serious complications involving the pancreas and kidneys.

“Our findings highlight important risks that should be carefully monitored in people taking these drugs,” Al-Aly said. “Physicians must remain vigilant for signs of pancreatitis and routinely monitor kidney function, as kidney problems often progress silently until they are at an advanced stage.”

As the use of GLP-1RA medications grows, this study provides a resource for health care providers navigating the balance between the drugs’ benefits and risks.

“GLP-1RA drugs can have broad health benefits,” Aly-Aly said. “However, they are not without risks. Our findings underscore the possibility for wider applications for these medications but also highlight important risks that must be managed in clinical practice.”

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!
Related Videos
Related Content
Advertisement
Study finds low-income patients face uphill battle fighting health insurance denials: ©Stuart Miles - stock.adobe.com
July 15th 2025

Low-income patients face uphill battle when fighting health insurance denials, Umass research finds

Off the Chart: A Business of Medicine Podcast - Ep. 73: Why physicians are suing RFK Jr., with attorney Richard H. Hughes IV, J.D., M.P.H.
July 14th 2025

Ep. 73: Why physicians are suing RFK Jr., with attorney Richard H. Hughes IV, J.D., M.P.H.

DOJ drops charges against Utah physician accused in COVID-19 fraud scheme © Tada Images - stock.adobe.com
July 14th 2025

DOJ drops charges against Utah physician accused in COVID-19 fraud scheme

Zed Williamson and the Physician Growth Accelerator Podcast featured on Medical Economics
June 21st 2025

The peril of relying on one person at your practice

primary care word cloud: © ibreakstock - stock.adobe.com
July 10th 2025

Optum, other health insurers are gaining more and more control of primary care across the country: study

Matt Coursen: ©JLL
July 9th 2025

Does your real estate support the growth plans of your private practice?

Related Content
Advertisement
Study finds low-income patients face uphill battle fighting health insurance denials: ©Stuart Miles - stock.adobe.com
July 15th 2025

Low-income patients face uphill battle when fighting health insurance denials, Umass research finds

Off the Chart: A Business of Medicine Podcast - Ep. 73: Why physicians are suing RFK Jr., with attorney Richard H. Hughes IV, J.D., M.P.H.
July 14th 2025

Ep. 73: Why physicians are suing RFK Jr., with attorney Richard H. Hughes IV, J.D., M.P.H.

DOJ drops charges against Utah physician accused in COVID-19 fraud scheme © Tada Images - stock.adobe.com
July 14th 2025

DOJ drops charges against Utah physician accused in COVID-19 fraud scheme

Zed Williamson and the Physician Growth Accelerator Podcast featured on Medical Economics
June 21st 2025

The peril of relying on one person at your practice

primary care word cloud: © ibreakstock - stock.adobe.com
July 10th 2025

Optum, other health insurers are gaining more and more control of primary care across the country: study

Matt Coursen: ©JLL
July 9th 2025

Does your real estate support the growth plans of your private practice?

About
Advertise
Contact Us
Editorial Staff
Job Board
Terms and Conditions
Contributor Guidelines
Privacy Policy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.